Research articlePublished 10 Dec 2013
Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Oral anticoagulants of the coumarin type have an inconveniently narrow therapeutic window, making their use difficult. In Mexico, genetic variables that participate in the heterogeneity of the therapeutic response remain poorly investigated. With the focus on warfarin, extensive pharmacogenomic studies have been performed, including those on the CYP450 family and APOE. The objective of this study was to determine the contribution of CYP2C9, CYP2C19, and APOE polymorphisms to the variations in response to the doses of acenocoumarol, which is the main anticoagulant prescribed to the Mexican population. The polymerase chain reaction–restriction fragment length polymorphism method was applied to identify *2 and *3 of CYP2C9, *2 of CYP2C19, and APOE variants. The genetic distribution of every polymorphism tested showed high variability when compared with other populations worldwide.
Keywords
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalGenetics and Molecular Research
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “J.A. Nastasi-Catanese”
- BylineArticles whose byline prints “J.R. Padilla-Gutiérrez”
- BylineArticles whose byline prints “Y. Valle”
- BylineArticles whose byline prints “F. Ortega-Gutiérrez”
- BylineArticles whose byline prints “M.P. Gallegos-Arreola”
- BylineArticles whose byline prints “L.E. Figuera”